Myriad Genetics Inc reports results for the quarter ended March 31 - Earnings Summary

Myriad Genetics

06/05/2025 22:46

Myriad Genetics Inc MYGN.OQ reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -1 cents.  The mean expectation of seventeen analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -8 cents to -3 cents per share.

Revenue fell 3.1% to $195.90 million from a year ago; analysts expected $200.56 million.

Myriad Genetics Inc's reported EPS for the quarter was breakeven results​.

The company reported a quarterly loss of $100 thousand.

Myriad Genetics Inc shares had fallen by 13.2% this quarter and lost 43.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 340.1% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy," 6 "hold" and 4 "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "hold"

Wall Street's median 12-month price target for Myriad Genetics Inc is $14.00

This summary was machine generated from LSEG data May 6 at 09:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.06
-0.03
Beat
Dec. 31 2024
0.03
0.03
Met
Sep. 30 2024
0.02
0.06
Beat
Jun. 30 2024
-0.01
0.05
Beat